Evidence includes the co-localisation of complement proteins and activation products with amyloid plaques and tau tangles in post-mortem Alzheimer’s disease brain [12–15], and the presence of complement activation products in Alzheimer’s disease CSF and plasma [8–11]. This evidence concerns the gene MAPT and Alzheimer disease.